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M.bovis BCG vaccination against tuberculosis (TB) notoriously displays variable protective efficacy in
different human populations. In non-human primate studies using rhesus macaques, despite efforts to
standardise the model, we have also observed variable efficacy of BCG upon subsequent experimental
M. tuberculosis challenge. In the present head-to-head study, we establish that the protective efficacy of
standard parenteral BCG immunisation varies among different rhesus cohorts. This provides different
dynamic ranges for evaluation of investigational vaccines, opportunities for identifying possible corre-
lates of protective immunity and for determining why parenteral BCG immunisation sometimes fails. We
also show that pulmonary mucosal BCG vaccination confers reduced local pathology and improves
haematological and immunological parameters post-infection in animals that are not responsive to in-
duction of protection by standard intra-dermal BCG. These results have important implications for
pulmonary TB vaccination strategies in the future.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) remains a major global health issue in spite of
widespreadM. bovis BCG vaccination campaigns for many years [1].
Protection conferred by live M. bovis BCG, which is administered
routinely by intra-dermal injection, is variable, depending on the), elma.tchilian@pirbright.ac.
erley).
P experiment: F.A.W.V.
and pulmonary BCG: P.C.L.B.
d, Woking, Surrey GU24 0NF,
ay Disease Infection Section,
ege London, London, UK.
Ltd. This is an open access article utarget population [2,3]. Both intrinsic and environmental factors
such as age, genetic predisposition and mycobacterial pre-
exposure, as well as possible BCG strain variation and virulence of
prevalent M. tuberculosis (M.tb) strain(s) have all been suggested to
influence the efficacy of BCG [4e6]. However, the mechanisms ul-
timately determining the success (or failure) of BCG to protect from
TB infection or disease remain poorly understood.
To improve TB prevention better immunisation strategies are
required [7]. However, without conclusive mechanistic insights
into protective immunity or correlates of vaccine induced protec-
tion, the development of a better TB vaccination strategy than BCG
remains largely empirical. Animal models therefore play a pivotal
role in vacccine development, providing proof-of-concept for pro-
tective efficacy and enabling head-to-head evaluation of candidates
to identify the most effective vaccines to progress to clinical trials
[8]. Amongst these, non-human primate (NHP) macaques are
considered to be of primary importance. Like humans, macaquesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
F.A.W. Verreck et al. / Tuberculosis 104 (2017) 46e57 47are naturally susceptible to M.tb infection and patho-
physiologically exhibit most of the typical characteristics of hu-
man TB disease [9]. The (partial) protective efficacy of BCG vacci-
nation in rhesus monkeys was reported four decades ago [10e13]
andmore recently a number of vaccine candidates have been tested
in rhesus and cynomolgus macaques [14e22].
Macaques are geographically widespread, genetically distinct
populations are well recognised and they are outbred [23]. Our
laboratory was the first to suggest that the protective efficacy of
BCGmay vary in different macaques [24]. In that study BCG showed
little protective efficacy in rhesus macaques while in cynomolgus
macaques there was reduced TB disease after prior BCG vaccina-
tion, although the numbers of animal were too small for the dif-
ference to reach statistical significance. These findings were
unexpected in the light of the early studies, but later we demon-
strated protective effects of BCG (as well as investigational candi-
date vaccines) in rhesus macaques [17], although occasional
experiments during this period failed to show any reduction of
disease burden following parenteral BCG vaccination.
Recently there has been increased interest in using the NHP
model as an important step in vaccine development [9], but as BCG
is frequently used as a “gold standard” positive control in the
evaluation of novel vaccines, variability in the response to BCG is a
potential confounding factor. Here we summarise the findings of
our earlier studies and in order to rule-out formally inter-
experimental variation we describe a simultaneous head-to-head
comparison of two rhesus cohorts of different breeding back-
ground in a BCG vaccination-M.tb challenge experiment. We
demonstrate differential efficacy of BCG in NHP cohorts, reminis-
cent of the clinical performance of BCG and providing the oppor-
tunity to identify factors that affect BCGmediated protection and to
determine correlates of protection.
In the light of the failure of the first parenteral TB booster vac-
cine in an efficacy trial [25], alternative immunisation strategies are
being evaluated. Pulmonary mucosal immunisation has the
advantage of targetting the portal of entry of M.tb and may induce
responses that can inhibit early growth of the organism as well as
inducing tissue resident memory cells [26e29]. Therefore, as a
second objective, we investigated the efficacy of local pulmonary
BCG vaccination in this rhesus model. Furthermore, prompted by
observations in mice that simultaneous systemic and local BCG
administration, a strategy termed SIM-BCG [26], significantly im-
proves the outcome of experimental TB infection, we sought proof
for this beneficial synergistic effect in NHP rhesus macaques. Im-
mune monitoring confirmed BCG vaccine take by intra-dermal and
pulmonary immunisation, while cutaneous recall testing supported
the notion that separate immune memory compartments are tar-
geted by the two routes of immunisation. We show that pulmonary
vaccination reduces local pathology in rhesus monkeys that are not
protected by standard intra-dermal BCG vaccination, a result with
important implications for the development of future vaccine
strategies.
2. Materials and methods
2.1. Experimental design
Rhesus macaques (Macaca mulatta) used in these studies were
all captive bred for research purposes. For each, experiment ani-
mals were from a single homogeneous breeding origin, unless
specified otherwise (in the case of direct cohort comparison).
Rhesus genotype was confirmed by mitochondrial DNA typing for
maternal descent, which validated the identification of animals as
Chinese or Indian type rhesus monkeys [30]. Healthy animals were
selected and shown to be immunologically naive to mycobacterialexposure prior to the start of the study by standard tuberculin skin
testing (TST) by palpebral injection and DTH readout within 72 h
using Mycobacterium tuberculosis (M.tb) tuberculin (Old Tubercu-
lin) made up according to the manufacturer's instructions (Syn-
biotics Corporation, San Diego, CA). Additionally, an interferon-
gamma release assay was shown to be negative prior to starting
the experiment using whole blood or freshly isolated PBMC and
purified protein derivative of M. tuberculosis (PPD, Statens Serum
Institute (SSI), Copenhagen), M. bovis and M. avium (both from
Prionics AG, Schlieren-Zürich) for specific in vitro recall stimulation.
Animals were stratified into treatment groups of N ¼ 6 animals
each. Random distribution was used for the following stratification
parameters whenever relevant and applicable: gender, age, body
weight and indicators to warrant social pair-wise housing. Specific
treatment was assigned to the groups randomly.
Prior to starting, NHP study protocols were approved by the
institutional animal use and care committee as a prerequisite of
Dutch law on the use of animals in scientific research. All housing
and animal care procedures were in compliance with European
directive 86/609/EEC and later 2010/63/EU, as well as the “Standard
for Humane Care and Use of Laboratory Animals by Foreign In-
stitutions” provided by the Department of Health and Human
Services of the US National Institutes of Health (NIH, identification
number A5539-01). Experiments were limited in time by study
protocol and pre-defined humane endpoints were in place to avoid
severe animal discomfort. BPRC acquired AAALAC accreditation in
2012.
Animals were housed throughout in appropriately classified
experimental facilities at BPRC with treatment groups randomly
distributed over the animal rooms. All animal handling and bio-
sample collection was executed under sedation by intramuscular
injection of ketamine (10 mg/kg). Heparinised blood for immune
monitoring, EDTA blood for standard haematology, and serum for
C-reactive protein measurement were collected by venipuncture at
specific time points defined by protocol. All clinical and patholog-
ical readings were done while blinded for treatment.
2.2. BCG vaccination
Where appropriate, animals were left untreated as non-
vaccinated controls or immunised with BCG Danish 1331 (SSI,
Copenhagen) by intra-dermal injection of a standard human dose
of 0.1 mL of a stock solution of 2e8x106 CFU/mL (unless specified
otherwise, see below). BCG was prepared freshly according to
manufacturer's instructions immediately prior to immunisation.
For each experiment sufficient vials were admixed into a single
pool of reconstituted BCG, and all animals were immunised from
this pool in random order within less than 2 h from vaccine prep-
aration. For SIM-BCG treatment half a standard human dose in
0.1 mL was injected intra-dermally and half a dose in 10 mL of
sterile saline solution (Eurovet Animal Health B.V., Bladel) deliv-
ered into the lung using a bronchoscope. For pulmonary mucosal
vaccination only, a single human dose of BCG was administered in
10 mL of saline solution endobronchially.
2.3. Mycobacterium tuberculosis infection
For infectious challengewe initially used 1000 CFU ofM.tb strain
Erdman (historical studies A, C and D). This lot of M.tb strain Erd-
man was obtained from a seed vial kindly provided by P. Andersen
(SSI, Copenhagen) and which was cultured, aliquoted and stored,
courtesy of D. van Soolingen (RIVM, Bilthoven). For historical study
B only we used Beijing strain HN878 at 1000 CFU per dose to assess
if a highly virulent, clinical isolate of M.tb would provide a more
stringent model with a greater window of opportunity for finding a
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kindly provided by M. Reed and C. Barry III (NIAID, NIH, Bethesda,
MD). Infectious challenge was achieved by intra-tracheal instilla-
tion after intubation of a catheter to the depth of the carina. All
animals in any single experiment were infected from a single sus-
pension of M.tb in a single session and in random order.
Later, for the prospective head-to-head comparison study in this
paper, we infected with 500 CFU of M.tb strain Erdman K01 (stan-
dard lot S-1), which was prepared as a global harmonisation strain
from a seed lot from the Trudeau Institute under a collaborative
agreement between WHO and CEBR/FDA with the assistance of
Aeras, cultured and filled by Mycos Inc. (CO). M.tb strain Erdman
K01 challenge was performed by endobronchial instillation using a
bronchoscope.
2.4. Immune response analysis
Lymphocyte stimulation tests were used to analyse vaccine
induced immunity with readout of specific NHP interferon-gamma
(IFNg) secretion by ELISA or ELISPOT (both U-CyTech, Utrecht). For
immune readout by IFNg ELISA, freshly isolated PBMC were seeded
in triplicate in 0.2 mL of 25 mM HEPES buffered RPMI culture
medium, supplemented with penicilin/streptomycin and 10% fetal
calf serum, at 200,000 cells per well in a 96-well round-bottom
microtiter plate. Cells were either stimulated or not with myco-
bacterial purified protein derivative (PPD, SSI, Copenhagen) at a
final concentration of 5 mg per mL and incubated for 3 days at 37 C
and 5% CO2. Secreted IFNg levels were measured by ELISA.
A so-called indirect ELISPOT procedure (UCy-Tech, Utrecht) was
used to determine the frequency of IFNg producing cells after BCG
vaccination and M.tb challenge. In brief, 200,000 freshly isolated
PBMC were incubated in triplicate in RPMI culture medium in
0.1 mL per well in 96-well flat-bottom microtiter plates for 24 h.
Cells were stimulated with M.tb PPD or a recombinant fusion pro-
tein of ESAT6 and CFP10 (produced at LUMC according to K. Franken
et al. [31]), both at a final concentration of 5 mg per mL, or left
unstimulated as a negative (medium) control. Subsequently, cells
were transferred to specific anti-IFNg coated filter plates (PVDF,
Millipore) for an additional overnight (18 h) incubation and spots
were developed using biotinylated anti-IFNg detector antibody,
streptavidin-horseradish peroxidase conjugate and tetrame-
thylbenzidine substrate (the latter from MAbTech, Stockholm).
Spots were quantified using an automated reader (AELVIS,
Hannover).
For immunogenicity screening post-BCG by tuberculin skin
testing (TST) animals received a Mantoux injection of tuberculin OT
(Synbiotics Corporation, San Diego, CA) in 0.1 mL, or 0.1 mL of
sterile saline control solution in their upper back. After 72 h in-
jection sites were scored for erythema and induration (adapted
Draize score [32]), and biopsies were taken with a circular
dermatological knife of 8 mm in diameter. Skin biopsies were
treated for 1 h with 1 mg/mL collagenase D and 0.2 mg/mL DNase I
(Roche, Mannheim) and homogenised using GentleMACS™ (Mil-
tenyi) to allow for cytometric analysis of the skin resident and
recruited lymphocytes. Lymphocytes were stained and charac-
terised as CD14-CD20-CD3þ cells on a LSR-II cytometer (Becton
Dickinson) and using FlowJo® software.
2.5. Clinical measurements and pathological assessment
Before and after infection and at study endpoint, clinical mea-
sures were recorded to assess TB disease progression. Body weights
were recorded at all sedation/bleeding time points. Standard hae-
matology was performed using a Sysmex 2000i (Siemens); C-
reactive protein (CRP) levels were determined using a Cobas™Integra400þ (Roche Diagnostics). At endpoint animals were sacri-
ficed in random order and underwent full pathologic evaluation
based on gross and histologic examination as previously described
[17]. Limited by capacity and logistics these endpoint evaluations
took place over a period of 13 days. Gross pathology was recorded
and scored according to an algorithm as before [17] or as published
by Lin et al. [21] with minor adaptation (large coalescing lesions
receiving a maximum score of 4 for prevalence and a score of 3 for
size). After collecting small representative samples for histopa-
thology and cryopreservation, whole lungs were minced and
homogenised as described previously. In the rhesus cohort com-
parison study lungs (lung slices) were randomly sampled by the
principle of stereology [33]. Serial dilutions of lung homogenates
were plated (in duplicate) on 7H10 Middlebrook agar plates con-
taining 100mg/L cycloheximide to determine the number of colony
forming units (CFU) as a measure of bacterial load in the infected
lung.
2.6. Statistical analysis
Throughout the manuscript, when depicting results of individ-
ual animals, colour coding for each of the N ¼ 6 animals per
treatment group is consistent (blue, green, magenta, red, black,
brown) to allow for comparison of individual results between as-
says and readouts at a glance. Results were statistically evaluated
using GraphPad Prism™ and non-parametric Mann-Whitney
testing for identifying statistically significant differences between
group medians.
3. Results
3.1. Historical variation in protection of macaques by intra-dermal
BCG immunisation: a retrospective analysis
While developing and refining a rhesus model for TB vaccine
research we noticed the variable outcome of BCG vaccination and
subsequent M.tb challenge. Retrospective analysis suggested that
the genetic background of the rhesus macaques was a confounding
factor in the results (not shown). From that point we further
standardised our experiments and ensured that animals for each
experiment were of similar genotype. Thus, using group sizes of
N ¼ 6 only, we could demonstrate protective effects of BCG and
investigational regimes over non-vaccinated controls, reaching or
approaching statistical significance ([17], and unpublished). How-
ever, despite standardisation, in two experiments we found no
signs of protection by BCG. In Table 1 we summarise retrospectively
the animal and treatment group characteristics of four indepen-
dent, historical studies. Studies A and B exemplify successful pro-
phylactic BCG vaccination in rhesus monkeys, whereas studies C
and D show a failure of BCG to protect. (Of note: data from study A
have been published previously [17], and are listed here solely for
reference purpose. Data from studies B, C and D were hitherto
unpublished.)
Regardless of the variation between individual animals and
irrespective of the different pathology levels observed in these
experiments, we could detect distinct effects of BCG vaccination on
gross (macroscopic) pathology in studies A and B, but not C and D
(Fig. S1). Group median total pathology scores (as a percentage of
total possible score) of non-vaccinated controls versus BCG vacci-
nees were 37% versus 14%, 7.0% versus 0%, 9.0% versus 6.5%, and 32%
versus 26%, for studies A to D respectively. BCG vaccine take was
confirmed in all studies by a specific increase of mycobacterial PPD
stimulated IFNg response post-vaccination (Fig. S2). The differential
BCG vaccine effect in these studies was reflected both by pulmo-
nary pathology and by extra-thoracic, disseminated TB-associated
Table 1
A retrospective analysis: standard intra-dermal BCG vaccination can be variably efficacious in NHP rhesus monkeys.
Study A Study B Study C Study D
Protective BCG Effect Yes Yes No No
Group Size (N ¼ n) 6 6 6 6
Rhesus Spectrotype Chinese Chinese Indian Chinese
Gender, proportion of males 100% 50% 100% 100%
Age (years ± sd) 7.8 ± 0.6 6.8 ± 1.7 7.2 ± 2.9 8.0 ± 1.0
Body Weight (kg ± sd) 8.9 ± 2.0 5.7 ± 1.8 10.2 ± 2.8 9.3 ± 1.6
BCG Vaccine Strain (2e8 x105 CFU) Danish 1331 Danish 1331 Danish 1331 Danish 1331
M.tb Challenge Strain (1000 CFU) Erdman HN878 Erdman Erdman
Time Interval from Vaccination to Infect 18 weeks 18 weeks 18 weeks 18 weeks
Follow-up Time Post-Infection 17 weeks 17 weeks 17 weeks 24 weeks
Animal and treatment group characteristics and experimental conditions of 4 independent, historical TB vaccination-infection experiments in rhesus macaques (Macaca
mulatta) are summarised. For studies A to D, naive animals were selected from single populations and confirmed by mitochondrial DNA typing to be of homogeneous
spectrotype (Chinese or Indian rhesus). (Data from study A have been published previously [17]).
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(Table S1). Other clinical measures of TB disease and protective BCG
vaccine effect, e.g. body weight alteration and changes in serum
levels of CRP and haematological erythrocyte-associated values,
sometimes reached statistical significance in studies A and B, but
never in studies C and D (Table S1).
None of the animal and experimental design characteristics of
the historical studies listed in Table 1 - genotype (i.e. Chinese versus
Indian type rhesus), gender, age, body weight, BCG vaccine dose/
strain, M.tb challenge dose/strain, time interval from vaccination to
infection and from infection to endpoint - explained the failure of
BCG to (partially) protect from TB disease after M.tb challenge in
studies C and D. Study C was a prospective study anticipating BCG
failure on the basis of earlier analyses and selection of animals from
a specific cohort. In study D, however, the lack of protective effect of
BCG was unexpected. Thus, from these historical studies we
learned that the outcome of BCG vaccination seems to be critically
determined by unknown factors intrinsically associated with the
population of rhesus macaques used in each study.
3.2. Head-to-head comparison of protective response of different
macaques to intra-dermal BCG immunisation
Despite our standardisation efforts, however, we could not
exclude formally the possibility of accidental variations in experi-
mental conditions compromising BCG efficacy. Therefore, we
designed a prospective head-to-head BCG vaccination-M.tb infec-
tion study of two rhesus cohorts. The animals were obtained from
different breeding facilities and represented different - Indian
versus Chinese - genotypes. Animals were vaccinated as before
with a standard human dose of BCG Danish 1331 intra-dermally
and 17 weeks later they were challenged with M.tb harmo-
nisation strain Erdman K01 by endobronchial instillation. Non-Table 2
Experimental setup and details of study design.
Treatment Treatme
T1 non-vaccinated non-v*
T2 BCG vaccinated, intra-dermally (i.d.) BCG*
T3 non-vaccinated non-v
T4 BCG vaccinated, intra-dermally (i.d.) BCG
T5 Pulmonary BCG vaccinated MUC
T6 Simultaneously pulmonary & i.d. BCG vaccinated SIM
Prospective head-to-head comparison of two cohorts of rhesus macaques comprising N ¼
rhesusmacaques, standard (human) intra-dermal BCG Danish 1331 vaccinationwas comp
and figures). Non-vaccinated controls were enroled from week 12 post-BCG onwards. Ad
N ¼ 6 Chinese rhesus macaques were immunised by endobronchial instillation with
administration of a standard dose of BCG, half intra-dermally and half by endobronchia
500 CFU of M.tb strain Erdman K01 endobronchially and followed for another 13 weeksvaccinated (non-v) control animals were enroled later, at week 12
post-primary BCG, five weeks prior toM.tb challenge. The details of
the experimental set-up are summarised in Table 2 (see treatment
groups T1 to T4 in particular).
Immunogenicity of intra-dermal BCG vaccination was moni-
tored by specific IFNg ELISPOT upon in vitro recall stimulation with
mycobacterial PPD during the vaccination phase of the study. In
both rhesus populations PPD specific IFNg responses could be
detected above background and with similar kinetics and similar
amplitude (Fig. 1). The IFNg response curves indicate similar
immunogenicity of the vaccine in both rhesus cohorts.
To determine BCG vaccine efficacy, vaccinees and non-
vaccinated controls from both rhesus populations were infected
with M.tb strain Erdman in a single randomised session. Two non-
vaccinated controls of the Indian rhesus cohort reached the hu-
mane endpoint in weeks 8 and 11 post-infection, and pathological
examination upon euthanasia confirmed severe pathology in both
animals (which are represented in Fig. 2A, B and C in the non-v*
designated treatment group by blue and magenta symbols,
respectively). The remaining animals were all culled in random
order at the endpoint according to protocol. Lung pathology,
disseminated disease and bacterial burden in the lung was broadly
more prominent in Indian than in Chinese type animals (Fig. 2, see
non-v* and non-v designated groups, respectively). BCG vaccina-
tion reduced these parameters of disease and infection in the In-
dian type rhesus, but failed to do so in the animals of Chinese
genotype (Fig. 2). BCG vaccination reduced group median lung
pathology, extra-thoracic disseminated pathology, and lung colony
forming units (CFU) in Indian rhesus (Fig. 2A, B, C, respectively),
while no such protective effects were observed in Chinese type
animals (Fig. 2D, E, F). This head-to-head study demonstrates that
standard intra-dermal BCG vaccination can fail to protect some
populations of rhesus macaques. Taken together with the historicalnt Abbreviated Rhesus Genotype BCG Danish 1331 Dose
Indian n.a.
Indian 5  105 CFU
Chinese n.a.
Chinese 5  105 CFU
Chinese 5  105 CFU
Chinese (2.5 þ 2.5) x105 CFU
6 animals in treatment groups T1 to T4. In each cohort of Indian and Chinese type
ared to non-vaccinated controls (non-v* and BCG* indicate Indian type rhesus in text
ditionally, sharing standard BCG and non-vaccinated controls (T3 and T4), groups of
a standard human dose of BCG (abbreviated as MUC, T5) or by the simultaneous
l instillation (SIM-BCG, T6). All animals were challenged 17 weeks post-BCG with
at max until endpoint.
Fig. 1. IFNg response upon BCG vaccination in two distinct rhesus populations. In a
prospective head-to-head comparison the immune response to BCG vaccination was
monitored in two distinct rhesus cohorts by specific NHP IFNg ELISPOT assay. The
frequency of IFNg producing cells, detected upon in vitro stimulation with mycobac-
terial PPD, indicated similar efficacy of BCG vaccine take in Indian and Chinese type
rhesus. Group averages of control corrected values (þstandard error) are plotted over
time.
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correlate with the genotype - Indian versus Chinese.3.3. Immune responses after pulmonary and parenteral vaccination
with BCG
While BCG in man is routinely administered by intra-dermal
injection, BCG delivered by aerosol has previously been suggested
to improve protection over intracutaneous injection in rhesus
monkeys [11] as well as in mice and guinea pigs [26,34e36]. More
recently, simultaneous local mucosal and systemic administration
of BCG, so-called SIM-BCG, was shown to provide additional pro-
tective efficacy in a mouse model and significantly decreased the
lung M.tb load compared to immunisation by either route alone
[26]. To re-assess pulmonary mucosal BCG vaccination in rhesus
macaques (abbreviated as MUC) and to evaluate SIM-BCG, two
additional groups of N ¼ 6 of the same Chinese rhesus cohort were
included in the study (Table 2, T5 and T6 for MUC and SIM-BCG,
respectively). Again, vaccination and infection were performed
from single BCG vaccine and M.tb challenge suspensions, in single
sessions and with animals from all treatment groups handled in
random order.
The immune response post-vaccination was monitored by spe-
cific IFNg ELISPOT using freshly isolated PBMC. As soon as 3 weeks
after vaccination frequencies of antigen specific IFNg producing
cells were significantly increased over baseline values in all three
vaccine groups, standard intra-dermal BCG, MUC and SIM (Fig. 3A).
The highest levels of IFNg response were obtained at week 9 post-
vaccination in the standard BCG group, significantly higher than in
the MUC but not SIM-BCG group. The MUC PBMC IFNg response
remained significantly lower compared to standard BCG up toweek
16, 1 week before infectious challenge (p ¼ 0.028 by Mann-
Whitney). Nevertheless, up to that point, all three vaccine groups
displayed significantly elevated IFNg responses. At study week 16,
the group median IFNg response values were 147.5, 45.0, and 115.0
for BCG, MUC and SIM, respectively, and highly significantly greater
than the median of 10 spots per million in non-vaccinated control
animals (Fig. 3A).
Twelve weeks after primary vaccination a tuberculin skin test
(TST) was performed to assess the antigen specific recall response
in vivo. Although classical DTH responses of induration or erythema
were not informative if recordable at all, skin biopsies from PPDinjection versus saline control sites revealed significant mycobac-
terial antigen associated influxes of CD3þ T cells upon flow cyto-
metric analysis (Fig. 3B). Local T cell recruitment in the skin was
most prominent in the two groups immunised with BCG intra-
dermally and significantly above the median specific T cell influx
in the MUC group. Yet, despite the pulmonary route of vaccination,
MUC treated animals also showed significant antigen-specific
recruitment of T cells to the TST site over that in non-vaccinated
controls (Fig. 3B).
In summary, immune response monitoring by ELISPOT and TST-
DTH site analysis confirmed vaccine take. The decreased PBMC and
skin responses of the MUC group are in accordance with the
expectation that pulmonary vaccination preferentially induces a
lung homing immune response [36e38].
3.4. Protective effect of pulmonary compared to intra-dermal BCG
immunisation
The results of M.tb challenge of the MUC and SIM groups
compared to non-v and standard BCG groups are shown in Fig. 4.
Median lung pathology scores are 22.0 and 26.0 for non-v and
standard BCG respectively, while the median scores for MUC, 6.5,
and SIM, 10.0, show a strong trend toward a decrease (p ¼ 0.061 by
Mann-Whitney for MUC in comparison to non-v controls) (Fig. 4A).
Note, however, that the pulmonary immunisation of the MUC and
SIM groups is not identical because the SIM animals received half
the lung dose of BCG given to MUC treated monkeys. Disseminated
extra-thoracic pathology scores were relatively low and not
significantly different between any of the groups, although
appearing worse in the standard BCG group compared to non-v,
MUC and SIM (Fig. 4B, not significant). Individual CFU counts
from the lungs displayed considerable variation as expected, but
median values of 10log CFU were 3.16 and 3.18 for MUC and SIM,
respectively, and about half a log lower in comparison to non-v and
BCG animals with medians of 3.64 and 3.69, respectively (Fig. 4C).
These results confirm earlier data indicating the superiority of
pulmonary mucosal over parenteral immunisation with BCG in
NHPs, but more importantly indicate that pulmonary delivery can
show a protective effect under circumstances when standard intra-
dermal BCG fails to induce protection. It is not clear from these data
whether SIM can provide superior protection against M.tb chal-
lenge in NHPs since the systemic component (intra-dermal BCG) of
the SIM regime failed, indeed may have been deleterious, in this
cohort.
3.5. Clinical and immunological indicators of protective efficacy of
pulmonary BCG
As in human TB, NHP macaques can show clinical signs of dis-
ease after experimental M.tb infection, which can be used as a
readout of treatment efficacy. Severe loss of body weight (wasting)
has been reported previously in M.tb infected Chinese type rhesus
macaques [17], but was not prominent in the present cohort for
reasons unclear at the moment. Levels of CRP, an acute phase
protein in the serum reflecting systemic inflammation, were
elevated after M.tb challenge in most animals, but highly variable
andwithout significant difference between the treatment groups in
this experiment (median change in CRP over the infection period:
21.1, 32.6, 12.0, and 12.2 mg/L for non-v, BCG, MUC and SIM,
respectively).
Beside body weight and CRP we also recorded haematologic
alterations from the start of the infection until endpoint. Red blood
cell associated measures of mean corpuscular volume (MCV) and
mean corpuscular hemoglobin (MCH), reflecting infection associ-
ated anemia, are decreased in non-v and BCG vaccinated animals in
Fig. 2. Head-to-head analysis of differential protective effect of BCG in distinct rhesus populations. Groups of N ¼ 6 rhesus macaques were either vaccinated by standard intra-
dermal BCG or left unvaccinated, and 17 weeks later infected by endobronchial M.tb. The top panels (A-C) present results from the Indian rhesus cohort (non-v* versus BCG*); the
bottom panels (D-F) from the Chinese rhesus cohort (non-v versus BCG). At endpoint animals were sacrificed for evaluation of TB disease and infection. Lung pathology (A, D) and
extra-thoracic TB lesions (B, E) were scored in arbitrary units. Mycobacterial burden was enumerated from random lung sample homogenates (C, F). Colour coding of individual
animals per treatment group is consistently applied throughout the manuscript to allow for correlation at glance. Horizontal lines represent group median values. P-values by
Mann-Whitney testing reached significance only for the Indian type rhesus cohort for lung and disseminated pathology scores only (top panels A and B, respectively).
F.A.W. Verreck et al. / Tuberculosis 104 (2017) 46e57 51particular (Fig. 5A and B). Prior MUC and SIM treatment, however,
reduces the adverse effect of M.tb infection on the erythrocyte
compartment (Fig. 5A and B).
The ratio of monocytes over lymphocytes (Mo/Lf ratio) has been
identified as a risk factor for TB in BCG vaccinated children [39],
while we have previously identified a correlation between Mo/Lf
ratio post-infection and the severity of TB pathology in rhesus
macaques (unpublished). In this study infectious challenge resulted
in increased Mo/Lf ratios over the infection period in the non-v
control and BCG groups, but not in the MUC or SIM treated ani-
mals (Fig. 5C).
Altogether, while systemic inflammation assessed by serum CRP
did not reveal a clear vaccine effect, alterations in haematologic
measures of the erythrocyte compartment (MCV, MCH) as well as
Mo/Lf ratio post-infection provide suggestive evidence of decreased
disease severity and protective efficacy of local pulmonary but not
standard intra-dermal BCG vaccination.
3.6. Immune responses post-M.tb infection
As well as measuring IFNg responses of PBMC after vaccination
to provide evidence of vaccine take, immune responses were
monitored by specific ELISPOT after infectious challenge. IFNgresponses 1 week before infection are highest in the animals that
received intra-dermal BCG (BCG and SIM groups) (see above and
Fig. 3A, week 16 post-vaccination). That response pattern is un-
changed 1 week after challenge, but by week 3 post-infection the
pattern changes completely (Fig. 6A and B). Both MUC and SIM
vaccinated animals at week 3 display significantly lower IFNg re-
sponses after in vitro PPD stimulation in comparison to standard
BCG vaccinated animals (p¼ 0.004 and p¼ 0.026, respectively) and
non-v controls (p¼ 0.009 and p¼ 0.041, respectively) (Fig. 6A). The
greatest differences inmedian response values between pulmonary
mucosal vaccination strategies (MUC and SIM) versus standard
intra-dermal BCG and non-v controls are apparent at the peak of
the PPD specific IFNg response at week 6 with group medians of
1100, 1147, 5941 and 5688 spots per million respectively, albeit
statistically less robust (Fig. 6C).
IFNg release against ESAT6 and CFP10, two antigens that are
absent from BCG and therefore in this experiment specifically
associated with M.tb infection, revealed similar response kinetics
(Fig. 6D). While 1 week post-challenge no ESAT6-CFP10 response
was detectable (Fig. 6E), at week 6 the MUC and SIM treatment
groups show lower median IFNg responses than BCG and non-
vaccinated controls (713, 344, 2207 and 2201, respectively; for
SIM vs non-v, p ¼ 0.065) (Fig. 6F).
Fig. 3. Immunogenicity of pulmonary and SIM BCG vaccination. A) The frequency of antigen specific IFNg secreting cells in freshly isolated Chinese rhesus PBMC was determined
by specific ELISPOT. Group averages of (medium control corrected) PPD specific responses (þstandard error) are plotted for standard intra-dermal BCG (BCG), pulmonary BCG (MUC)
and SIM-BCG treatment groups over time up to 16 weeks post-vaccination. Non-vaccinated control animals were included in the analysis from week 12 onward. B) Twelve weeks
post-BCG vaccination a standard tuberculin skin test (TST) was performed by the intra-dermal injection of tuberculin or saline control. Three days later the skin injection sites were
sampled and processed for flow cytometric evaluation. The individual specific influx of CD3þ T lymphocytes upon tuberculin over saline in vivo recall stimulation is plotted with
horizontal lines indicating group medians. Colour coding of individual animals in each treatment group is consistently applied throughout to allow for correlation at a glance (for
animals in non-v and BCG treatment groups as in Fig. 2). All differences between MUC and BCG, MUC and SIM, MUC and non-v are significant with p ¼ 0.0043, 0.0152 and 0.0152
respectively (by Mann-Whitney).
Fig. 4. Gross pathology and lung bacterial load. Intradermal BCG, pulmonary BCG and SIM-BCG treated Chinese rhesus monkeys (BCG, MUC, and SIM, respectively) were
challenged by endobronchial infection with M.tb strain Erdman and 13 weeks later sacrificed for pathological and bacteriological evaluation of protective efficacy. A) Lung and B)
extra-thoracic TB pathology were determined by pre-defined arbitrary scoring algorithm. C) Mycobacterial burden was enumerated from random lung sample homogenates by
plating serial dilutions. Horizontal lines represent group medians. Colour coding of individual animals as in Fig. 3. The p value of the difference in median lung pathology between
MUC versus non-v by Mann-Whitney is 0.061; for all other comparators: p > 0.01.
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vaccination and M.tb challenge could be due to more efficient
homing of IFNg producing effector cells to the local sites of infec-
tion, to a better control of bacterial replication, or to both. In any
case, since the magnitude of PBMC TB antigen specific immune
responses post-M.tb challenge has repeatedly been shown to
correlate with disease severity [17,40,41], the immune response
patterns observed are compatible with improved prognosis after
pulmonary MUC or SIM immunisation with BCG.
4. Discussion
To our knowledge this is the first study to show in a head-to-
head experiment that Chinese and Indian rhesus macaques may
either develop some protective immunity or fail to do so in
response to parenteral BCG immunisation. Parenteral BCGvaccination in rhesus macaques has previously been reported to
provide partial protection against intratracheal, endobronchial or
aerosol infection using M.tb strain Erdman or H37Rv and a chal-
lenge dose ranging from 14 to 3000 CFU [10,12,16,17,20]. However,
failure of standard intra-dermal BCG to protect in rhesus macaques,
despite immunological evidence of vaccine take, has been
demonstrated previously in a small study comparing the response
to BCG of cynomolgus and Indian type rhesus macaques; a finding
ascribed to genetic factors [24]. The hitherto unpublished historical
data from Chinese and Indian macaque vaccination-infection ex-
periments described here, together with the head-to-head exper-
iment, illustrate variability in protective efficacy of parenteral BCG
in both Indian and Chinese type rhesus macaques, but taken
together show that this difference is not due to the genotype of the
animals. The data reported here and the head-to-head evaluation in
particular, exclude the possibility that variability in BCG efficacy
Fig. 5. Changes in haematological values following infectious challenge. Changes in clinical values over the infection period are depicted for A) mean corpuscular volume (MCV),
B)mean corpuscular hemoglobin (MCH) and C) ratio of monocyte to lymphocyte counts (Mo/Lf ratio). Colour coding of individual animals as in Fig. 3, and horizontal lines indicating
group median values. The p value of the difference in median change in MCH of MUC versus non-v by Mann-Whitney is 0.084; for all other comparators: p > 0.1.
Fig. 6. IFNg responses post-M.tb infection. Immune responses post-infection were monitored using freshly isolated PBMC and a specific IFNg ELISPOT assay. PBMC were stim-
ulated in vitro with PPD (A-C) or a recombinant ESAT6-CFP10 (E6C10) fusion protein (D-F). A, D) Group averages of saline control corrected frequencies of IFNg secreting cells
(þstandard error) are plotted over time. Individual results with horizontal lines indicating group medians, are plotted at 1 week B, E) and the peak of response at week 6 C, F).
Colour coding of individual animals as in Fig. 3. At the peak, p ¼ 0.24 and p ¼ 0.18 for MUC versus BCG and non-v respectively, and p ¼ 0.065 for both SIM versus BCG and SIM versus
non-v (Mann-Whitney).
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blood or at the DTH skin site. Nor can variation in theM.tb challenge
be the cause of BCG failure in the Chinese rhesus cohort. Although
recently lack of protection after immunisation of Indian rhesus was
ascribed to use of a high challenge dose of 275 CFU of M.tb Erdman
K01 [22], the present data using the same challenge strain from the
same source, indicate that BCG efficacy can be demonstrated irre-
spective of challenge dose, but is affected by other factors (seebelow).
It remains possible that genetic differences between rhesus
macaque populations explain the variability of parenteral BCG ef-
ficacy, for example, in genes controlling immune functions not
measured by our assays for T cell immunity. However, as animals in
our experiment were protected by endobronchially administered
BCG, this does not seem likely. It is therefore tempting to speculate
that environmental parameters may alter the (innate) immune
F.A.W. Verreck et al. / Tuberculosis 104 (2017) 46e5754status of macaques and the efficacy of BCG, as has been suggested
for man (see below).
BCG has long been known to vary geographically in efficacy [2],
an effect often ascribed to exposure to environmental mycobacteria
(EM), and a growing body of evidence shows that alterations to the
gut microbiota can have profound effects on subsequent immune
responses. Experimentally, oral or parenteral immunisation of mice
with EM can block subsequent induction of protective immunity by
parenteral BCG or subunit vaccines [42,43]. Similarly, the presence
or absence of a single species of microorganism can profoundly
alter the balance between TH17 cells, shown to be important in
protection of cynomolgus macaques after BCG immunisation [44],
and IL-10 producing Treg in mice [45e47]. Intestinal helminths in
man and Helicobacter pylori in NHPs and man, are implicated in
modulating immunity to tuberculosis [48,49] and interestingly,
different macaque populations have been found to harbour distinct
intestinal bacterial communities [50].We speculate that differences
in the microbiota might account for the variability of protective
immunity induced by parenteral BCG in rhesus macaques.
In addition to demonstrating variability in the protective effi-
cacy of BCG in different NHPs, we show in this study that pulmo-
nary mucosal administration of BCG can overcome the failure of
parenteral BCG. Although a very recent study in (Indian type)
rhesus macaques has failed to demonstrate a significant improve-
ment of pulmonary BCG delivered 11 weeks after parenteral BCG
[51], abundant evidence indicates that delivery of TB vaccines to the
respiratory tract mucosa is highly effective. Direct comparisons in
mice indicate that both BCG and subunit vaccines are more
[26,36,38,52] or at least equivalent in efficacy when delivered
mucosally [26,36]. Also, in accordance with what we report here in
NHP, in DBA/2JRj mice that are not protected by parenteral (sub-
cutaneous) BCG vaccination, intranasal mucosal administration of
BCG overcomes susceptibility and confers protection by an IL17-
dependent mechanism [53]. In guinea pigs very small numbers of
BCG organisms delivered by aerosol are as potent as much larger
numbers delivered parenterally [54,55]. In cattle endobronchial is
at least as protective as parenteral BCG delivery [56], while endo-
bronchial or aerosol administered BCG induced a stronger lung
immune response [57,58] and had superior protective efficacy to
parenteral BCG in NHPs [12]. Skin test conversion has been re-
ported in humans exposed to a BCG aerosol [59].
Although mucosal BCG is effective in animal models, currently
BCG is administered parenterally to humans. However, parenteral
boosting with subunit vaccines has so far not proved dramatically
effective in improving parenteral BCG efficacy over BCG alone,
either in animal models [52] or humans [25]. In contrast mucosal
boosting after parenteral BCG can provide markedly improved ef-
ficacy inmice [38,52] and guinea pigs [60]. In the light of these data,
and because pulmonary mucosal and parenteral immunisation
induce very different immune responses (see below), the alterna-
tive immunisation strategy of simultaneous parenteral and
mucosal immunisation (SIM) was investigated and shown to be
effective in mice [26,27]. SIM with parenteral BCG and endobron-
chial administration of a subunit vaccine has also been shown to be
highly effective in cattle [56]. However in the present experiments,
although a SIM BCG groupwas included, the protective effect in this
group is difficult to interpret, since parenteral BCG alone failed to
induce protective immunity.
Nevertheless there are good reasons to continue to explore the
efficacy of (pulmonary) mucosal delivery and SIM (reviewed in
Ref. [61]). Immune responses to M.tb infection in the lungs are
delayed [62] so that M.tb grows unchecked for the first two weeks,
even in parenterally immunized animals [27,63,64]. In contrast, in
mice immunized by the respiratory route M.tb does not grow for
the first week [26,27]. This may be due to the nature of immunecells induced by different routes of immunisation. In mice, after
parenteral immunisation antigen specific cells are found in lung
tissue, but after mucosal immunisation or respiratory infection,
they are also found in bronchoalveolar lavage (BAL) [65,66]. These
tissue resident T cells (TRM) play an important role in protection
against other respiratory infections (for example influenza, Sendai
or respiratory syncytial viruses) in mice and have distinct pheno-
typic properties [28,67,68]. In humans lung T cells differ in many
respects from those in blood and are enriched for cells that can
respond to respiratory pathogens [29], while PPD responsive T cells
are found in BAL of skin test positive donors [69].
However, although in mice parenteral and pulmonary immu-
nisation result in distinct patterns of localisation of antigen specific
cells in the lungs, when NHPs or humans were immunized paren-
terally or by aerosol with the vaccine candidate MVA85A, neither
systemic nor BAL cellular responses differed dramatically [70,71].
This might be a technical issue attributable to the nature of the
aerosol, as particles with a maximal size of 4 mm, which reach the
lower respiratory tract (LRT), induce strong BAL responses and
powerful systemic immunity in NHPs. In contrast immunisation of
the upper respiratory tract (URT) induces much weaker lung and
systemic responses [72], a result reminiscent of experiments in
mice showing that URT immunisation induces poor responses in
the LRT [37]. However, as is the case for parenteral vaccines
including BCG, powerful LRT immune responses do not necessarily
equate to protection. When the Aeras-402 vaccine (recombinant
adenovirus type-35 (rAd35) expressing Ag85A, Ag85B and TB10.4)
was administered as an aerosol to NHPs, it induced strong and
prolonged BAL CD4 and CD8 T cell responses and transient re-
sponses in the blood [73], but there was no protection against M.tb
challenge [22].
This result was attributed to the high dose (275 CFU) of M.tb
used for challenge, but it is also possible that the vaccine activates
inappropriately the innate immune system, although inducing a
TH1 like immune response. In a mouse experiment, parenteral
priming with a recombinant Ad5 expressing Ag85A was followed
by a mucosal boost with the same construct or a VSV recombinant
also expressing Ag85A. Both regimes induced equally strong LRT T
cell immune responses, but only the mice primed and boosted with
the adenoviral construct were protected against M.tb challenge
[74]. The Ad boost stimulated, whereas VSV blunted (through
increased IFNb production), IL12 responses and anti-mycobacterial
host defence. In other experiments activation of NK cells via IL-21
contributed to early non-specific protection against M.tb chal-
lenge, so that there may be several pathways to protective immu-
nity against tuberculosis [61]. Much other evidence indicates the
importance of innate immunity in protection against M.tb [62,75],
while BCG induces a state of “trained immunity” in macrophages
[76]. The innate signals activated by Ad35 (used in Aeras-402,
above) are not known, but different adenoviruses vary greatly in
efficacy as vaccine vectors [77], although only a minority have been
tested by the (pulmonary) mucosal route.
5. Conclusions
Both parenteral and pulmonary mucosal immunisation regimes
may fail for multiple reasons, but the failure of parenteral BCG to
protect in some NHP experiments has important implications for
development of TB vaccines. Clearly the use of parenteral BCG as a
“gold standard” positive control vaccine is fraught with difficulties.
Assessment of parenteral/parenteral, parenteral/pulmonary
mucosal prime boosts, or in our case a SIM BCG regime, is impos-
sible when parenteral BCG immunisation fails. On the other hand,
investigation of the reasons for failure of parenteral BCG in NHPs
might throw light on the mechanism of the variation in BCG
F.A.W. Verreck et al. / Tuberculosis 104 (2017) 46e57 55efficacy in humans [78]. It is intriguing that endobronchial BCG is
effective in NHPs when parenteral immunisation fails and that after
oral adminstration of EM or BCG, mucosal administration over-
comes the failure of a parenterally administered subunit vaccine to
protect against M.tb challenge in mice [43]. We suggest that one
reason to pursue further work on pulmonary mucosal immunisa-
tionwith both subunit vaccines and BCG, may be because this route
might circumvent at least some of the geographical variation in
protection after immunisation against tuberculosis.
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